Technological advances allow the assessments of multiple genes, e.g., via next-generation sequencing, in a relatively cost-effective manner. As the ability to assess up to thousands of genes by ordering one test becomes more available, determining which genes should be tested, and when in the workup, needs to be determined.
In the article by Wang et al. 1 in this issue of Neurology ® , the authors evaluated a 197-gene polyneuropathy panel in 93 patients suspected of having an inherited polyneuropathy. Eighteen causative mutations were found in 17 patients. Unsurprisingly, yield was highest in those patients with early onset, defined as younger than 40 years, and with a family history. The authors propose an algorithm for when to do genetic testing in such patients and provide a cost-savings analysis to justify the cost of the gene panel.
This article addresses important issues in utilizing genetic testing where the test involves hundreds of genes. One of the most important is that they are investigating a well-defined patient population in which an inherited polyneuropathy is highly suspected. Genetic testing does not replace a thorough history and physical examination, i.e., a good clinical assessment. Even in this well-defined patient population with high likelihood of inherited polyneuropathy, and using a panel surveying nearly 200 genes, only 17 of 93 patients had definite disease-causing mutations.
1 Certainly yield will be higher as more genetic causes are found, but multigene testing will not solve the issue of idiopathic polyneuropathy.
As indicated, in this study the investigators used a panel of genes associated with polyneuropathy. The authors had previously investigated whole-exome sequencing in suspected inherited polyneuropathy. Whole-exome sequencing assesses all known protein-coding genes in the genome. The authors briefly discussed some of the problems and pitfalls with this approach. One is depth of coverage of the genes assessed, i.e., likelihood of discovering different mutations in the gene investigated. 1 Another is the false-positive result of discovering mutations unrelated to polyneuropathy, and the ethical issues related to addressing these. Using a panel of genes specific for the disease of interest should minimize this false-positive issue, although it does not remove it completely. In the current study, in addition to the 18 known pathologic mutations found, 4 rare allelic variants and 2 novel copy number changes were found that were predicted to be disease-causing, but had not been previously described as such.
1 Also, the authors found one patient with a mutation associated with small fiber neuropathy, but that patient did not have a phenotype of small fiber neuropathy. Is this a false-positive result or is this early evidence for phenotypic expansion that occurs when genetic testing becomes more widespread? Also implicit is that genetic testing should be reserved for well-defined patient populations; patients with poorly defined pathology or vague symptoms will have a high falsepositive rate.
The authors present an algorithm for when to order genetic testing in patients with a chronic, slowly progressing, length-dependent polyneuropathy: again, a very well-defined patient population in which inherited polyneuropathy is suspected. 1 They recommended that multigene testing panel be done early in the workup if the age at onset is less than 40 years, and if a definitive family history is present. This is reasonable, provided that the cost is not too onerous for the patient. However, candidate gene testing may have a role prior to ordering a multigene panel; for example, PMP22 duplication/deletion testing may be more cost-effective for Charcot-Marie-Tooth type 1A in someone with suspected inherited polyneuropathy who has notable demyelinating features on nerve conduction studies. In the algorithm, further nongenetic testing is recommended on those patients without early onset or meaningful family history, based on the type of polyneuropathy and examination features; genetic testing is still considered in these patients but later in the course of the workup. 1 The authors estimated cost savings by utilizing their polyneuropathy panel early in the workup, which if positive, would halt further diagnostic testing. They estimated that the average cost for the workup of their 93 patients was around $13,000 per patient. At a cost of $1,000-$1,500 for their multigene panel, with a positive test rate of 20%, there would be a cost savings of 8%-12%. With early-onset and definite family history patients, the cost savings would be double, at 17%-21%. Although multigene testing is becoming less expensive because of technological advances, it is still expensive. A case needs to be made to insurance providers to pay for this testing even if no treatment is available.
The article by Wang et al. is an important step in determining what genetic testing should be done and when in the evaluation of suspected inherited polyneuropathy. Although this is a focused patient population, it highlights important concepts that need to be addressed in determining genetic testing for any condition.
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